Adjuvant Chemo-Immunotherapy May Improve NSCLC Survival
Postsurgical chemo-immunotherapy offers improved survival rates for patients with NSCLC, compared to adjuvant chemotherapy alone, according to a small phase III study.
First-line Nivolumab/Ipilimumab Demonstrate ‘Deep,’ ‘Durable’ Activity
Treatment with nivolumab and ipilimumab is clinically active and has a manageable safety profile for chemotherapy-naive patients diagnosed with advanced NSCLC.
Early Recognition of Immunotherapy Toxicities Essential
Oncology teams need to spot emerging immune-related adverse events associated with immunotherapies early in order to avoid treatment discontinuation.
